HEXYON

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland

Active ingredients

The drug HEXYON contains a combination of these active pharmaceutical ingredients (APIs):

1 Diphtheria toxoid UNII 3U7E3O07S8 - CORYNEBACTERIUM DIPHTHERIAE

Read about Diphtheria toxoid

2 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

3 Pertussis toxoid

Read about Pertussis toxoid

4 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

5 Poliomyelitis, serotype 1 UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

6 Poliomyelitis, serotype 2 UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

7 Poliomyelitis, serotype 3 UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

8 Hepatitis B, purified antigen

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. Read about Hepatitis B, purified antigen

9 Haemophilus influenzae B UNII F2TW0N64FI - HAEMOPHILUS INFLUENZAE TYPE B

Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. Read about Haemophilus influenzae B

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA09	Diphtheria-Haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1613247, 1613258, 1668494, 1678013
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 113829006, 113829007
Country: FR	Base de données publique des médicaments	Identifier(s): 60645557
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1070037, 1070038, 1070039, 1070040, 1070041, 1070042, 1070043, 1080530, 1080531
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100139373